Trial Profile
Phase 2 Open-Label, Multi-Center Study to Evaluate the Safety and Efficacy of Sunitinib Malate in Combination With AMG 386 as First Line or Second Line Therapy for Subjects With Metastatic Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Oct 2020
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary) ; Trebananib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Sponsors Amgen
- 16 Jul 2019 Status changed from active, no longer recruiting to completed.
- 02 Nov 2018 Planned End Date changed from 30 Nov 2018 to 17 Dec 2019.
- 26 Mar 2018 Planned End Date changed from 29 Mar 2018 to 30 Nov 2018.